Weight Loss Peptides: FDA-Approved Options vs Everything Else

If you're researching peptides for weight loss, you've likely encountered a confusing landscape. Social media influencers promote various peptides. Med spas offer "peptide therapy." Online sellers advertise products at a fraction of brand-name prices. And somewhere in the mix, you've heard about Ozempic and Wegovy.

Here's the clarity you need: not all peptides are the same. Some have been rigorously studied in clinical trials involving thousands of patients. Others have never been tested in humans. The difference isn't just academic—it directly impacts your safety.

As a naturopathic doctor specializing in metabolic health, I've seen patients achieve remarkable results with FDA-approved peptide therapies. I've also seen patients come to me after bad experiences with unregulated alternatives. This guide will help you understand exactly what's available, what's proven, and what you should avoid.

The Weight Loss Peptide Landscape in 2026

The peptide market has exploded. What was once a niche topic in bodybuilding forums has become mainstream conversation. Everyone from celebrities to your neighbor seems to be talking about peptides.

But "peptides" is a broad category. It includes:

FDA-approved medications with extensive clinical data, standardized manufacturing, and legal prescription status.

Compounded versions of approved medications, created by pharmacies that mix medications to order—sometimes during drug shortages, sometimes to offer cheaper alternatives.

Unapproved peptides that have shown interesting results in research settings but have never been approved for human use.

"Research" peptides sold online with labels explicitly stating they're not for human consumption—yet many people inject them anyway.

These categories are not equivalent. Understanding the differences could be the most important thing you learn about peptide therapy.

What Peptides Are Actually FDA-Approved for Weight Loss?

Let me be direct: four peptide medications are FDA-approved for chronic weight management — semaglutide, tirzepatide, liraglutide, and setmelanotide. Two of them account for nearly all current prescribing, but the list is not two names long, and the four are not interchangeable.

• Semaglutide (Wegovy) — chronic weight management in adults with obesity or with overweight plus a weight-related condition, and in patients aged 12 and older with obesity
• Tirzepatide (Zepbound) — chronic weight management in adults with obesity or with overweight plus a weight-related condition
• Liraglutide (Saxenda) — chronic weight management, approved back in 2014, for adults with overweight plus a weight-related condition and for patients aged 12 and older with obesity
• Setmelanotide (Imcivree) — approved only for specific rare genetic and acquired causes of obesity, not for general obesity

Note what is not on that list. Ozempic and Mounjaro are the same molecules as Wegovy and Zepbound, but they are approved for type 2 diabetes, not for weight management. Using them for weight loss is off-label prescribing, which is legal but is a different thing from an FDA-approved indication.

Semaglutide and liraglutide are GLP-1 receptor agonists; tirzepatide is a dual GIP/GLP-1 agonist. They work by mimicking hormones your body naturally produces to regulate appetite and blood sugar. Setmelanotide works through an entirely different pathway. Here's what you need to know about each — starting with the risks, because that is the part most articles bury.

Serious Risks: What the FDA Labels Actually Warn About

FDA Boxed Warning — thyroid C-cell tumors. Wegovy, Zepbound, and Saxenda each carry an FDA Boxed Warning, which is the agency's most serious warning. In rodents, semaglutide, tirzepatide, and liraglutide caused thyroid C-cell tumors at clinically relevant exposures. Whether they cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans is unknown, because the human relevance of the rodent findings has not been determined. All three are contraindicated — not "worth mentioning," but contraindicated — in anyone with a personal or family history of MTC or with multiple endocrine neoplasia syndrome type 2 (MEN 2). Setmelanotide does not carry this boxed warning.

Acute pancreatitis. Reported with GLP-1 receptor agonists. If pancreatitis is suspected, the medication should be stopped and you should be evaluated.

Acute gallbladder disease. Gallstones and gallbladder inflammation occurred in the clinical trials, and rapid weight loss independently raises gallstone risk.

Delayed gastric emptying and aspiration under anesthesia. These medications slow how quickly the stomach empties — that is part of how they work. In late 2024, the FDA added a warning to the GLP-1 class labels describing rare postmarketing reports of pulmonary aspiration during general anesthesia or deep sedation in patients who had food still in the stomach despite fasting as instructed. Tell every surgeon, anesthesiologist, proceduralist, and dentist that you are on one of these medications before any planned procedure. This one is easy to forget and genuinely dangerous.

Other labeled warnings include severe gastrointestinal reactions, acute kidney injury from dehydration, hypoglycemia when combined with insulin or an insulin secretagogue, hypersensitivity reactions including anaphylaxis and angioedema, increased heart rate, and worsening of diabetic retinopathy in people with type 2 diabetes.

This is a summary, not the label. Read the Medication Guide that comes with the prescription, and go through it with the clinician prescribing it.

Semaglutide (Ozempic, Wegovy, Rybelsus)

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes. It received FDA approval for weight management in 2021 under the brand name Wegovy.

How it works:

• Mimics GLP-1, a hormone released after eating
• Slows gastric emptying so you feel full longer
• Reduces appetite signals in the brain
• Improves insulin sensitivity and blood sugar control

Clinical evidence: The STEP trials, involving over 4,500 participants, showed average weight loss of 15-17% of body weight over 68 weeks. Those are averages across thousands of people enrolled in a structured trial with diet and activity support, not a projection for any one patient. Individual results vary considerably, and some participants lost substantially less.

FDA-approved uses:

• Wegovy injection: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, and in patients aged 12 and older with obesity; also approved to reduce major cardiovascular events in adults with established cardiovascular disease and obesity or overweight
• Wegovy tablets: A once-daily oral form, approved December 2025, for the same cardiovascular risk reduction and weight reduction indications in adults
• Ozempic: Type 2 diabetes (weight loss is a secondary benefit)
• Rybelsus: Oral form for type 2 diabetes

Common side effects: Nausea, vomiting, diarrhea, constipation, and abdominal pain—typically most pronounced when starting or increasing doses, and often improving over time with gradual titration.

Tirzepatide (Mounjaro, Zepbound)

Tirzepatide is a dual GIP/GLP-1 receptor agonist, meaning it activates two hormonal pathways instead of one. This dual mechanism may explain its slightly enhanced efficacy.

How it works:

• Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors
• Provides similar appetite suppression and blood sugar benefits as semaglutide
• The dual action may enhance metabolic effects

Clinical evidence: The SURMOUNT trials showed average weight loss of 18-22% of body weight, somewhat higher than semaglutide. Again, these are trial averages under controlled conditions. Your result may be higher or lower.

FDA-approved uses:

• Zepbound: Chronic weight management in adults with obesity or with overweight plus a weight-related condition (approved 2023); also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity
• Mounjaro: Type 2 diabetes

Common side effects: Similar to semaglutide—primarily gastrointestinal symptoms that tend to improve over time.

Liraglutide (Saxenda, Victoza)

Liraglutide is the GLP-1 receptor agonist that got here first. Saxenda was approved for chronic weight management in December 2014, years before semaglutide, and it remains approved today. Victoza is the same molecule at lower doses for type 2 diabetes.

It gets less attention now for two straightforward reasons: it is a daily injection rather than a weekly one, and average weight loss in trials is lower than with semaglutide or tirzepatide. It carries the same FDA Boxed Warning for thyroid C-cell tumors and the same MTC/MEN 2 contraindication.

It still belongs in the conversation. When the newer medications are unaffordable or not covered by insurance, an FDA-approved older option is a genuinely different proposition from an unapproved or compounded one.

Setmelanotide (Imcivree)

Setmelanotide is a peptide, it is FDA-approved to reduce excess body weight, and it is not a general weight loss drug. It is an MC4 receptor agonist approved only for specific causes of obesity: acquired hypothalamic obesity, Bardet-Biedl syndrome, and genetically confirmed POMC, PCSK1, or LEPR deficiency. Its label states directly that it is not indicated for other types of obesity, including general (polygenic) obesity.

I include it because "FDA-approved for weight loss" is not one category. What a medication is approved for matters as much as whether it is approved, and a drug approved for a rare genetic condition tells you nothing about what will work for common obesity.

Semaglutide vs Tirzepatide: Which Is Better?

This is one of the most common questions I hear. The honest answer: both are effective, and the "better" choice depends on your individual situation.

Key considerations:

If cardiovascular protection matters: Semaglutide has FDA approval for reducing heart attack and stroke risk in patients with cardiovascular disease and obesity. Tirzepatide's cardiovascular trials are still ongoing.

If maximum weight loss is the priority: Tirzepatide shows slightly higher average weight loss in trials, though individual results vary significantly.

If you've tried one without success: Some patients who don't respond well to semaglutide do better with tirzepatide, and vice versa. The dual mechanism may work differently for different metabolic profiles.

If cost is a factor: Both are expensive without insurance. Your coverage may favor one over the other.

The decision should be made with a qualified prescribing clinician who understands your complete health picture, not based on social media recommendations or price alone.

What About All the Other Peptides?

Here's where I need to be very direct. Many peptides are marketed for weight loss, performance, or wellness benefits. You may have heard of:

• BPC-157 (marketed for healing and recovery)
• AOD-9604 (marketed for fat loss)
• CJC-1295/Ipamorelin (marketed for growth hormone release)
• MOTS-c (marketed for metabolism)
• Tesamorelin (FDA-approved only for HIV-associated lipodystrophy)

None of these are FDA-approved for weight loss. Most have never undergone rigorous human trials. Some show promising results in animal studies or small pilot studies, but that's very different from proven safety and effectiveness in humans.

The gap between "interesting in lab studies" and "proven safe and effective in humans" is enormous. Many promising compounds fail when they reach human trials—sometimes because they don't work, sometimes because they cause unexpected harm.

Using unapproved peptides means accepting unknown risks. You're essentially conducting an experiment on yourself with substances that haven't been properly studied.

The Compounded Peptide Problem

Compounding pharmacies can legally prepare customized medications when there is a valid prescription and a documented medical need. During the GLP-1 shortages of 2022 through 2024, compounders were permitted to make copies of semaglutide and tirzepatide. That window has closed — more on the specifics below, because this is the part of the peptide landscape that has changed most and the part most articles still have wrong.

Compounded medications are also fundamentally different from FDA-approved products:

What the Data Shows

The FDA has documented significant problems with compounded peptides:

• 455+ adverse event reports for compounded semaglutide
• 320+ adverse event reports for compounded tirzepatide
• Cases of incorrect dosing leading to hospitalizations
• Sterility failures and contamination
• Potency inconsistencies between batches

In September 2024, the FDA issued warnings about the risks of compounded semaglutide products, noting that they may contain salt forms of semaglutide that haven't been studied for safety.

The Shortage Window Has Closed

Federal law lets compounders make what amounts to a copy of an FDA-approved drug only in limited circumstances — one of which is when that drug is on the FDA's drug shortage list. Both drugs have come off that list:

• Tirzepatide: the FDA declared the shortage resolved on December 19, 2024. The period of enforcement discretion ended for state-licensed (503A) pharmacies on March 5, 2025, and for outsourcing facilities (503B) on March 19, 2025.
• Semaglutide: the FDA declared the shortage resolved on February 21, 2025. Enforcement discretion ended for 503A pharmacies on April 24, 2025, and for 503B outsourcing facilities on May 22, 2025.

Neither drug appears on the FDA drug shortage list or the 503B bulks list today. The FDA has gone further and proposed formally excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, on the finding that there is no clinical need for outsourcing facilities to compound them from bulk ingredients.

What that means for you in practice: a compounded copy of semaglutide or tirzepatide is no longer a reasonable workaround for cost or access, and a clinic still selling one is not sitting in the same gray area it might have been in 2024. If a provider offers you compounded semaglutide or tirzepatide today, ask them plainly what basis they are compounding it under and get the answer before anything is injected. I am not an attorney and this is not legal advice — but the question is yours to ask, and a clinic that can't answer it is telling you something.

Where Compounding Still Has a Narrow Role

Compounding itself is not the problem. It remains appropriate when an individual patient's needs genuinely cannot be met by the approved product — a documented allergy to an inactive ingredient, for example. What it is not is a discount parallel supply of a medication that is sitting on the shelf.

If a compounded medication is genuinely indicated for you, the basics still apply:

1. A legitimate prescription from a qualified prescribing clinician, for a documented clinical reason
2. A US-based, state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility
3. Documented potency and sterility testing
4. Proper medical oversight and follow-up

If a provider can't tell you exactly where their compounded peptides come from and what quality controls are in place, that's a significant red flag.

Research Peptides vs Pharmaceutical Grade

You may have seen peptides sold online at dramatically lower prices than pharmacy medications. Many are labeled "for research purposes only" or "not for human consumption."

These warnings are not legal technicalities. They're telling you the truth.

Research peptides are manufactured for laboratory use—for studying cells in petri dishes or testing in research animals. They are not manufactured to pharmaceutical standards because they're not intended to be injected into humans.

What "Research Grade" Actually Means

This is not hypothetical. In a 2024 study published in the Journal of Medical Internet Research, researchers test-purchased semaglutide from illegal online pharmacies that sold without a prescription, then analyzed what arrived. Every vial they received was assessed as a probable substandard or falsified product. Measured purity ranged from 7.7% to 14.37%, against the 99% claimed on the labels. The amount of semaglutide in the vials exceeded the labeled amount by roughly 29% to 39%. Bacterial endotoxin was detected in every sample.

That study analyzed three delivered vials, so it is a close look at a handful of products rather than a market-wide estimate. It is still a direct look at what actually shows up in the mail. When you inject a "research peptide," you genuinely don't know what you're putting into your body.

The Legal Reality

Selling research peptides for human use is illegal. Buying them to inject yourself occupies a legal gray area that offers you no protection. If something goes wrong, you have no recourse—no manufacturer liability, no pharmacy accountability, no regulatory oversight.

Benefits of FDA-Approved Peptides (When Done Right)

I don't want to leave the impression that peptide therapy is all risk. When using FDA-approved medications under proper medical supervision, the benefits can be significant:

Sustainable weight loss: Unlike crash diets that fail long-term, GLP-1 medications work with your body's natural hormone systems. Clinical trials show sustained weight loss over years of treatment.

Metabolic health improvements: Beyond the number on the scale, patients often see improvements in:

• Blood sugar and A1C levels
• Blood pressure
• Cholesterol profiles
• Inflammatory markers

Cardiovascular protection: Semaglutide has FDA approval for reducing the risk of major cardiovascular events in patients with established cardiovascular disease and obesity—a meaningful clinical benefit beyond weight loss.

Quality of life: Many patients report reduced food noise (constant thoughts about eating), better energy levels, and improved relationship with food.

The key phrase is "when done right." The same medication that helps one patient can harm another if the quality is compromised or medical oversight is lacking.

Are You a Candidate for FDA-Approved Weight Loss Peptides?

These medications aren't appropriate for everyone. General candidacy criteria include:

Likely candidates:

• BMI ≥30 (obesity), or
• BMI ≥27 (overweight) with at least one weight-related condition (high blood pressure, high cholesterol, type 2 diabetes, sleep apnea)
• No contraindications (see below)
• Willing to combine medication with lifestyle changes
• Able to commit to ongoing medical supervision

Contraindications — the FDA labels say these medications should not be used at all:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to the medication or any of its ingredients

Requires careful evaluation before prescribing (discuss with your prescribing clinician):

• History of pancreatitis
• Gallbladder disease
• Severe gastrointestinal disease or gastroparesis
• Pregnancy, or planning a pregnancy — the labels advise stopping at least two months beforehand — and breastfeeding
• History of eating disorders
• Diabetic retinopathy, in people with type 2 diabetes
• Any upcoming surgery or procedure requiring general anesthesia or deep sedation

Not a good fit if:

• You're looking for a "quick fix" without lifestyle changes
• You're unwilling to work with a prescribing clinician for monitoring
• You're primarily motivated by cosmetic rather than health goals
• You expect medication to do all the work without dietary and activity changes

Questions to Ask About Any Weight Loss Peptide

Before starting any peptide therapy, get clear answers to these questions:

1. "Is this peptide FDA-approved for weight loss?" Semaglutide, tirzepatide, and liraglutide are approved for general chronic weight management. Setmelanotide is approved only for specific rare genetic and acquired causes of obesity. Anything else is off-label at best, unapproved at worst.

2. "Is this the brand-name medication or compounded?" Know exactly what you're getting. If compounded, ask about the pharmacy and quality testing.

3. "Where is it manufactured?" FDA-registered facilities? US-based? Overseas? The answer matters.

4. "What monitoring will you provide?" Proper oversight includes baseline labs, regular follow-ups, and accessible support.

5. "What's your experience with these medications?" How many patients has this provider treated? What outcomes do they typically see?

6. "What happens if I have side effects or complications?" There should be a clear plan beyond "stop taking it."

The Bottom Line: Source and Oversight Matter

In the weight loss peptide landscape, you have real choices—but they're not all equivalent.

The well-supported path: FDA-approved medications (semaglutide, tirzepatide, or liraglutide), obtained through legitimate pharmacies, prescribed and monitored by a qualified prescribing clinician. This gives you studied efficacy, a known safety profile including the boxed warning and contraindications, quality assurance, and medical support.

No longer a gray area: Compounded copies of semaglutide and tirzepatide. The shortages that made them permissible were declared resolved in December 2024 and February 2025, and the FDA's enforcement discretion ended in 2025. Compounding still has a narrow role for an individual patient whose needs the approved product genuinely cannot meet — but it is not a discount channel, and it requires careful vetting of both the pharmacy and the provider.

What to avoid: Research peptides sold online, overseas-sourced products with unknown quality, any provider who can't answer basic questions about their sources and protocols.

The peptide you choose matters. But equally important is where it comes from and who's overseeing your treatment. A legitimate medication used without proper oversight can still cause harm. An excellent provider using questionable products can't protect you from quality issues.

Both matter. Don't compromise on either.

Key Takeaways

• Four peptides are FDA-approved for chronic weight management: semaglutide (Wegovy), tirzepatide (Zepbound), liraglutide (Saxenda), and setmelanotide (Imcivree, for specific rare genetic and acquired causes of obesity only)
• Wegovy, Zepbound, and Saxenda each carry an FDA Boxed Warning for thyroid C-cell tumors and are contraindicated in anyone with a personal or family history of MTC or with MEN 2
• These medications delay gastric emptying—tell any surgeon, anesthesiologist, or dentist before a procedure requiring sedation
• Tirzepatide shows slightly higher average weight loss in trials, but semaglutide has an approved cardiovascular indication; trial averages are not individual predictions
• Compounded semaglutide and tirzepatide are no longer covered by FDA enforcement discretion—both shortages were declared resolved and the discretion periods ended in 2025
• Research peptides are NOT for human use—in a 2024 test-purchase study, every online-sourced semaglutide vial analyzed was substandard, with measured purity of 7.7% to 14.37%
• Popular "wellness" peptides like BPC-157 and AOD-9604 are not FDA-approved for any indication
• Your peptide source and medical oversight matter as much as which peptide you choose

References

• FDA. WEGOVY (semaglutide) prescribing information — boxed warning for thyroid C-cell tumors, contraindications, indications, pancreatitis, gallbladder disease, and pulmonary aspiration under anesthesia
• FDA. ZEPBOUND (tirzepatide) prescribing information — boxed warning, contraindications, weight management and obstructive sleep apnea indications
• FDA. SAXENDA (liraglutide) prescribing information — boxed warning and chronic weight management indication
• FDA. IMCIVREE (setmelanotide) prescribing information — indications limited to acquired hypothalamic obesity, Bardet-Biedl syndrome, and POMC/PCSK1/LEPR deficiency
• FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — shortage resolution dates and the end of enforcement discretion for compounded semaglutide and tirzepatide
• FDA. FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list
• FDA. FDA's concerns with unapproved GLP-1 drugs used for weight loss — adverse event reports associated with compounded semaglutide and tirzepatide
• Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. J Med Internet Res. 2024;26:e65440. doi:10.2196/65440
• NIDDK. Prescription medications to treat overweight and obesity

Next Steps

If you're considering FDA-approved weight loss medications and want to discuss whether you might be a candidate, I'm happy to have that conversation. My approach focuses on metabolic health as a whole—not just a number on a scale—with proper monitoring and support throughout treatment.

Who I can see

Dr. Boomgaarden is a naturopathic doctor licensed in California, and provides naturopathic medical care to patients located in California. Care is delivered by telehealth, so patients across Orange County and the rest of the state are seen by secure video. If you are outside California, please ask what options are available before booking.

Ready to explore your options with a licensed naturopathic doctor who prioritizes your safety? Schedule a discovery call to discuss whether FDA-approved metabolic therapies could be part of your health plan.